Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Prostate, 2024

DOI: 10.1002/pros.24721

Links

Tools

Export citation

Search in Google Scholar

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractIntroductionThe 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.MethodsThe 2023 marked the 10th Annual CHPCA Meeting, a discussion‐oriented scientific think‐tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.ResultsThe central topic areas covered at the meeting included: targeting transcription factor neo‐enhancesomes in cancer, AR as a pro‐differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence‐driven precision medicine.DiscussionThis article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.